Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Current Medicinal Chemistry|February 1, 2024
Analysis of Clinical Success and Molecular Mechanisms of Action of Novel Anti-glioblastoma Drugs: A ReviewSabina Abdullaeva, Vladimir Chubarev, Anna Valeeva, et al.Annals of the Rheumatic Diseases|September 15, 2022
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III studyEugen Feist, Saeed Fatenejad, Sergey Grishin, et al.Annals of the Rheumatic Diseases|July 2, 2024
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatmentEugen Feist, Roy M Fleischmann, Saeed Fatenejad, et al.Current Medicinal Chemistry|March 19, 2025
Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.govSabina Abdullaeva, Polina Abdullaeva, Renata Gabdrahimova, et al.Annals of the Rheumatic Diseases|August 4, 2021
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III studyEvgeniy Nasonov, Saeed Fatenejad, Eugen Feist, et al.Rheumatology and Therapy|May 16, 2026
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)Roy M Fleischmann, Vibeke Strand, Eugen Feist, et al.Frontiers in Pharmacology|August 30, 2021
Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120Andrey Kulikov, Elena Shipaeva, Anastasia Dmitrieva, et al.Pageof 2